Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAALAD2 | Q9Y3Q0 | 3/20 | 0.63 |
| ▸ | FTO | Q9C0B1 | 8/20 | 0.62 |
| ▸ | TTR | P02766 | 1/20 | 0.56 |
| ▸ | JAK2 | O60674 | 1/20 | 0.56 |
| ▸ | NQO1 | P15559 | 1/20 | 0.55 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.55 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.53 |
| ▸ | MIF | P14174 | 1/20 | 0.50 |
| ▸ | DRD1 | P21728 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | BLM | P54132 | 1/20 | 0.49 |
| ▸ | SMAD3 | P84022 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.49 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8893358 | 0.99 | NAALAD2 (0.62) | NAALAD2FTOTTRJAK2NQO1 | |
| SCHEMBL12754623 | 0.94 | FTO (0.65) | NAALAD2FTOTTRJAK2NQO1 | |
| SCHEMBL15045059 | 0.92 | FTO (0.61) | NAALAD2FTOTTRJAK2NQO1 | |
| SCHEMBL18872864 | 0.91 | FTO (0.65) | NAALAD2FTOTTRJAK2NQO1 | |
| SCHEMBL15744221 | 0.89 | FTO (0.64) | NAALAD2FTOTTRJAK2NQO1 | |
| SCHEMBL20729848 | 0.89 | FTO (0.66) | NAALAD2FTOTTRJAK2NQO1 | |
| SCHEMBL991216 | 0.88 | FTO (0.63) | NAALAD2FTOTTRJAK2NQO1 | |
| SCHEMBL29353892 | 0.88 | FTO (0.63) | NAALAD2FTOTTRJAK2NQO1 | |
| SCHEMBL20809317 | 0.87 | FTO (0.70) | NAALAD2FTOTTRJAK2NQO1 | |
| SCHEMBL17956697 | 0.87 | FTO (0.69) | NAALAD2FTOTTRJAK2NQO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220218664-A1 | DRUG AND METHOD FOR TREATING OR PREVENTING COMPLICATIONS FROM DIABETES, USING SAID DRUG | SHOWA UNIVERSITY (JP) | 2022-07-14 | — | — | US | disclosed |
| US-20210322381-A1 | DRUG FOR TREATMENT OR PREVENTION OF BLOOD CEREBRAL HEMORRHAGE, AND METHOD FOR TREATING OR PREVENTING CEREBRAL HEMORRHAGE USING THE DRUG | CORXEL PHARMACEUTICALS HONG KONG LIMITED (CN) | 2021-10-21 | — | — | US | disclosed |
| US-20210000794-A1 | Drug and Method of Treating or Preventing Renal Disease Using Drug | SHOWA UNIVERSITY (JP) | 2021-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210322381-A1 | DRUG FOR TREATMENT OR PREVENTION OF BLOOD CEREBRAL HEMORRHAGE, AND METHOD FOR TREATING OR PREVENTING CEREBRAL HEMORRHAGE USING THE DRUG | PROC, FABP7, TIMP3 | NAALAD2 453/4885FTO 4532/4885TTR 201/4885 |
| US-20220218664-A1 | DRUG AND METHOD FOR TREATING OR PREVENTING COMPLICATIONS FROM DIABETES, USING SAID DRUG | SLC5A2, SLC5A1, IAPP | NAALAD2 786/4885FTO 1128/4885TTR 185/4885 |
| US-20210000794-A1 | Drug and Method of Treating or Preventing Renal Disease Using Drug | REN, ATP6V1B1, SLC10A1 | NAALAD2 378/4885FTO 2997/4885TTR 195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.